Schrödinger adds an­oth­er Big Phar­ma part­ner; Grey Wolf bags $3.3M to 'il­lu­mi­nate' tu­mors

Schrödinger has added yet an­oth­er large phar­ma com­pa­ny to its list of part­ners. The New York-based biotech signed a €10 mil­lion ($11 mil­lion) deal to im­prove Bay­er‘s drug dis­cov­ery ef­forts. As with their ex­ist­ing col­lab­o­ra­tions with As­traZeneca and Sanofi, Schrödinger will use their ma­chine learn­ing-based mol­e­c­u­lar de­sign tech­nol­o­gy to screen bil­lions of com­pounds to iden­ti­fy and op­ti­mize drug tar­gets. The news comes as Schrödinger aims to de­vel­op its own clin­i­cal pro­grams with three can­cer tar­gets, hir­ing trans­la­tion­al vet­er­ans from Mer­ck and Ei­sai to do so.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.